Among children with intermediate-risk rhabdomyosarcoma that is negative for a fusion gene, those who had a high score of the specific gene signature MG5 had poorer survival outcomes compared with those who had a low score of MG5.
This slideshow reviews vincristine, indicated for Hodgkin disease, Kaposi sarcoma, leukemia, neuroblastoma, non-Hodgkin lymphoma, rhabdomyosarcoma, and Wilms’ tumor.
Drugs that enhance oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor. These are the latest findings from the St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project
